Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2025-04-24 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings
2025-04-24 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the annual disclosure of encumbrance of shares by a promoter, pursuant to SEBI regulations. It states that no new encumbrance was made during the financial year ended March 31, 2025, other than those already disclosed. The document is a regulatory compliance disclosure related to share encumbrance, not a financial report, earnings release, or management discussion. It is a specific regulatory filing under SEBI (SAST) regulations, which fits best under the category of Regulatory Filings (RNS). The document length is short and it is a formal declaration, not a report or announcement of a report publication.
2025-04-19 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the company's declaration about the non-applicability of the Large Entities framework as per a SEBI circular. It is a regulatory compliance statement rather than a financial report or announcement of financial results. The document is short (1453 characters) and does not contain financial data, earnings, management discussion, or any report attachments. It is a regulatory filing related to compliance with SEBI regulations, not a report or announcement of voting results, capital changes, or management changes. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-04-18 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Share Transfer Agent for the quarter and year ended March 31, 2025. It confirms dematerialization and listing of securities, and is addressed to stock exchanges. The document length is 3248 characters, which is relatively short and primarily serves as a compliance certificate rather than a full financial report or detailed filing. It does not contain financial statements or detailed analysis. This fits the category of a Regulatory Filing (RNS), as it is a regulatory compliance certificate and does not qualify as an Annual Report, Interim Report, or any other detailed financial or management report.
2025-04-18 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notice from LASA Supergenerics Limited addressed to stock exchanges regarding the closure of the trading window for insiders ahead of the declaration of audited financial results for the quarter and year ended March 31, 2025. It references regulatory compliance with insider trading regulations and specifies the trading window closure period. The document does not contain any financial data, results, or detailed report content but is an announcement related to trading restrictions prior to financial results disclosure. Given its nature as a regulatory announcement about trading restrictions and not a financial report or earnings release, it best fits the category of Regulatory Filings (RNS). The document length is short (1626 characters), and it is not a report itself but an announcement related to compliance and trading window closure.
2025-03-27 English
Shareholders meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed Scrutinizer's Report on the voting results of an Extraordinary General Meeting (EOGM) held by Lasa Supergenerics Limited. It references the Companies Act, SEBI Listing Obligations, and provides consolidated voting results on a special resolution. The document includes the report of the scrutinizer appointed to oversee the e-voting process and the final voting outcome. This type of document is specifically related to the declaration of voting results from a shareholder meeting. It is not an announcement of a report publication, nor is it a full annual or interim report, audit report, or management report. The key phrase "Scrutinizer’s Report on Extraordinary General Meeting" and the detailed voting results confirm that this is a Declaration of Voting Results & Voting Rights Announcement filing.
2025-02-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.